Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,995 | 271 | 1,705 |
| Samples | 495 | 103 | 386 |
| Peptides | 412 | 81 | 336 |
Function
STIL · STIL centriolar assembly protein
This gene encodes a cytoplasmic protein implicated in regulation of the mitotic spindle checkpoint, a regulatory pathway that monitors chromosome segregation during cell division to ensure the proper distribution of chromosomes to daughter cells. The protein is phosphorylated in mitosis and in response to activation of the spindle checkpoint, and disappears when cells transition to G1 phase. It interacts with a mitotic regulator, and its expression is required to efficiently activate the spindle checkpoint. It is proposed to regulate Cdc2 kinase activity during spindle checkpoint arrest. Chromosomal deletions that fuse this gene and the adjacent locus commonly occur in T cell leukemias, and are thought to arise through illegitimate V-(D)-J recombination events. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000371877 | Q15468-2 | 559 | 394 |
| ENST00000360380 | Q15468 | 482 | 361 |
| ENST00000396221 | E9PSF2* | 479 | 358 |
| ENST00000337817 | A0A0A0MR87* | 475 | 355 |
Gene Properties
Recurrent Mutations
All 394 amino-acid changes on canonical ENST00000371877 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STIL · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STIL – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 33/612 5% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Melanoma | 4/210 2% | 58/1899 3% |
| Bladder Carcinoma | 3/58 5% | 24/956 3% |
| Plasma Cell Myeloma | 5/44 11% | 2/305 1% |
| Colorectal Carcinoma | 16/143 11% | 51/3239 2% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 16/810 2% |
| Esophageal Carcinoma | 1/23 4% | 13/769 2% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 23/1390 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Ovarian Carcinoma | 6/109 6% | 8/998 1% |
| Neuroendocrine Tumour | 6/154 4% | 3/577 1% |
| Other Solid Cancers | 0/94 0% | 18/1515 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Other Sarcomas | 2/69 3% | 5/699 1% |
| Biliary Tract Carcinoma | 3/54 6% | 6/950 1% |
| Gastric Carcinoma | 2/74 3% | 15/1809 1% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 17/2550 1% |
| Burkitts Lymphoma | 1/32 3% | 1/196 1% |
| Pancreatic Carcinoma | 4/89 4% | 8/1611 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 9/1592 1% |
| Hepatocellular Carcinoma | 2/46 4% | 10/2210 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Non-Cancerous | 2/104 2% | 2/830 0% |
Mutation Distribution
Where STIL is mutated · all tissues, split by cell line vs tissue
How many mutations in STIL were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,995 mutations in STIL
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|